Invasive laser acupuncture targeting muscle: a novel approach to protect dopaminergic neurons and reduce neuroinflammation in a brain of Parkinson’s disease model
Parkinson's disease (PD) affects 1-2% of the global population and presents significant therapeutic challenges. Due to the limitations of existing treatments, there is a pressing need for alternative approaches. This study investigated the effects of invasive laser acupuncture (ILA), which combines acupuncture and photobiomodulation. In this method, optical fibers are inserted into the muscle layers of the acupoint to enhance therapeutic outcomes. Mice with MPTP-induced PD were treated with ILA at 830 nm or 650 nm. Protective effects of nigrostriatal dopaminergic neurons and fibers were assessed by examining TH immunoreactivity in the brain. Neuroinflammation markers in the brain and muscle metabolomic profiles were also analyzed. Comparisons between invasive and non-invasive laser application, as well as the impact of nerve blocking with lidocaine, were also evaluated. ILA at 830 nm (ILA830) significantly improved motor performance and increased the nigrostriatal TH-positive immunoreactivities. It reduced the levels of α-synuclein, apoptotic proteins, and inflammatory cytokines, while increasing anti-inflammatory in the brain. ILA830 also decreased nigrostriatal astrocyte and microglia activation. Muscle metabolomic analysis showed distinct group clustering and significant changes in metabolites like glucose and galactose, correlating with improved motor functions. Invasive laser treatment was more effective than non-invasive, and lidocaine pre-treatment did not block its effects. ILA at 830 nm effectively ameliorates PD symptoms by protecting dopaminergic neurons, and reducing neuroinflammation in the brain. Muscle metabolomic changes by ILA830, such as increased glucose and galactose, correlate with motor improvement. This approach offers a promising strategy for PD treatment, warranting further research to optimize its use in clinical settings.
Authors
- Sora Ahn (ORCID: https://orcid.org/0000-0003-2572-0349)
- Hong-Seok Son
- In Jin Ha (ORCID: https://orcid.org/0000-0002-9210-1401)
- Myung Sook Oh (ORCID: https://orcid.org/0000-0001-8189-4066)
- In-Yeop Baek
- Min‐Ho Nam (ORCID: https://orcid.org/0000-0002-6191-1268)
- Eugene Huh (ORCID: https://orcid.org/0009-0001-1090-1705)
- Hi‐Joon Park (ORCID: https://orcid.org/0000-0002-0538-2664)
- Mijung Yeom (ORCID: https://orcid.org/0000-0002-4346-8549)
- Ju‐Young Oh (ORCID: https://orcid.org/0000-0001-9141-0133)
- Hyeong Jin Jeon (ORCID: https://orcid.org/0000-0003-3661-5157)
- Chang-Su Na (ORCID: https://orcid.org/0000-0001-5478-649X)
- Seong-Eun Park (ORCID: https://orcid.org/0000-0002-1021-1309)
- Juhan Park
Institutions
- University of Seoul (KR)
- Gachon University (KR)
- Dongshin University (KR)
- Kyung Hee Cyber University (KR)
- Korea University (KR)
- Kyung Hee University (KR)
- Korea Institute of Brain Science (KR)
Publication Details
- Journal
- Chinese Medicine
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1186/s13020-025-01104-2
- Citations
- 4
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 5.56
Funders
- National Research Foundation
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea